Biotech After-Hours Trading: FDA Decisions Don't Wait for Market Open

It’s 5:32 PM on a Tuesday. Your biotech just got FDA approval. The stock is up 35% in after-hours trading. Your broker’s extended-hours session is open for another 2 hours and 28 minutes. Do you sell now or wait for the morning?

The FDA announces most drug approval decisions between 4:00 PM and 7:00 PM ET, after the regular market close. If you trade biotech catalysts during regular hours only, you’re leaving 60-80% of the catalyst move on the table. But after-hours trading is a different animal: wide spreads, low liquidity, and the real risk that the initial spike reverses to flat by the next morning’s open.

Why the FDA Announces After the Close

The FDA does not coordinate with market hours. Approvals and CRLs are posted to the FDA website, and the company issues a press release simultaneously. Most decisions drop between 4:00 PM and 7:00 PM ET because that’s when the review division finishes its workday. A smaller number drop pre-market (6:00-9:00 AM ET). Almost never during the 9:30 AM-4:00 PM regular session.

This isn’t a conspiracy. It’s logistics. The FDA review team works a government schedule. They finalize the action letter, notify the company, and post to the public docket, all in the late afternoon. The result is that every PDUFA date (the FDA’s goal date for a drug decision) is an after-hours event. You can track upcoming PDUFA dates on the FDA advisory committee calendar.

Pattern 1: The Approval That Holds

A clean approval, full label, no boxed warning, no REMS requirement. The stock spikes 35% at 5:30 PM, drifts higher to 42% by 7:00 PM as more traders get the news, and opens up 38-40% the next morning. The pre-market fade is less than 5%.

These are the approvals where the first 30 minutes of after-hours are the best entry. The label is as good as the market hoped, institutional traders are buying, and the next day’s open confirms the after-hours price.

How to trade it: If you’re already holding, you can sell a portion into the after-hours spike (liquidity is sufficient for clean approvals). If you want to buy, a limit order 2-3% above the first print usually fills within the first hour. Don’t wait until 8:00 PM, the best liquidity is in the first 60-90 minutes after the announcement.

Pattern 2: The Approval That Fades

The drug is approved, but the label comes with baggage: a restricted patient population, a boxed warning, or post-marketing requirements that signal the FDA has concerns. Algorithmic traders bid it up on the word “approved” and sell into human traders who actually read the label.

The pattern: stock spikes 28% at 5:00 PM, is up only 12% by 7:00 PM, and opens up 5-8% the next morning. The fade accelerates in pre-market as institutional traders digest the label language and realize the commercial opportunity is smaller than expected.

How to trade it: If you’re holding and see the stock fading within 90 minutes of the announcement, sell. The institutional read is in, and it’s bearish. Do not assume the morning will bring a bounce, it usually brings confirmation of the fade.

Pattern 3: The CRL, No Bounce, No Recovery

A Complete Response Letter (CRL) drops. The stock gaps down 40-50% immediately. There is no bounce. After-hours liquidity dries up entirely, the bid disappears. If you’re holding through a PDUFA date and don’t have access to after-hours trading, you’re riding a 50% loss you can’t sell until 9:30 AM the next morning.

This is the single most important rule of biotech catalyst trading: if you hold into a binary event without after-hours access, your position size must be small enough that a 50% overnight gap doesn’t blow up your portfolio.

CRLs happen. The base rate from 2018-2022 was 37%, more than 1 in 3 drug applications were rejected. If you trade 10 PDUFA dates in a year, probability says 3-4 will be CRLs. Size accordingly.

The Mechanics of After-Hours Trading

Extended-hours sessions vary by broker but typically cover pre-market (4:00 AM-9:30 AM ET) and after-hours (4:00 PM-8:00 PM ET). The rules are different from regular hours:

• Only limit orders. Most brokers disable market orders in extended hours. This is a feature, not a bug, market orders in illiquid after-hours sessions would fill at catastrophic prices.
• Wider spreads. A biotech stock that trades with a $0.05 spread during regular hours might have a $1.50-$3.00 spread in after-hours (on a $50 stock). That’s a 3-6% spread vs. 0.1% during the day.
• Lower volume. After-hours volume is typically 10-20% of regular-hours volume, even for a catalyst stock. For a biotech approval, expect $5-20 million in after-hours volume vs. $50-100 million the next day.
• The right order type: For a buy, place a limit order 2-3% above the last print. For a sell, place a limit order 2-3% below the last print. This gives you a reasonable chance of execution without getting picked off by the wide spread.

Never use a marketable limit order (a limit order set at the ask for buys or at the bid for sells) in after-hours. The spread will eat 3-6% of your trade before you’ve made a decision.

The Pre-Market Fade

The after-hours move is noise. The regular-hours 9:30 AM open is where price discovery actually happens.

Overnight, institutional traders model the label, run the peak-sales math, and build their position. By 9:30 AM, the stock has found its level. This is why the most common pattern in biotech approvals is an after-hours spike that partially or fully reverses by the next morning’s open.

Rule of thumb: If you bought the after-hours spike, sell into the first 30 minutes of regular trading. If you want to buy the approval, wait for the 10:00 AM level to form, let the overnight traders establish the price before you commit.

The Checklist for Holding Through a PDUFA Date

1. Confirm your broker supports after-hours trading and that it’s enabled on your account.
2. Check your position size: a 50% overnight gap must be survivable.
3. Know the PDUFA time window: most decisions drop 4:00-7:00 PM ET.
4. Have your limit orders ready: sell limit 2-3% below last print for after-hours.
5. Pre-write your sell discipline: “If the stock gaps up 30%+ in after-hours and fades more than 10% from the peak in the first 90 minutes, I sell half.”
6. If it’s a CRL, do not chase a bounce that isn’t there. Take the loss and move on.

After-hours trading around FDA decisions is not about being fast. It’s about being prepared. The traders who lose money are the ones who see a 35% spike, panic-buy at the ask, and wake up to a stock that opened up 8%.

For how to position before the PDUFA date, read how to trade FDA catalysts. For options strategies around catalyst events, see trading biotech options around FDA catalysts. For the mechanics of what a CRL actually means for a drug, read what is a CRL.